Incremental therapeutic strategies assume that malignant systems fail gradually—through accumulated damage or progressive loss of function. Executable systems rarely fail in this manner.
Persistence ends abruptly when feasibility is lost, not when small improvements accumulate. As long as architectural limits are not exceeded, additional interventions tend to be accommodated within the same operational regime.
Durable control therefore depends on identifying the conditions under which executability becomes impossible, rather than continuing to optimize within architectures that remain feasible.
